Overview

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Status:
Terminated

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

Phase:

Phase 2

Details

Lead Sponsor:

Soligenix

Treatments:

Beclomethasone